KMTS Share Price Performance
US$27.32
5.48 (25.09%)
6.3% undervalued intrinsic discount
US$29.14
Fair Value
Price US$27.32
AnalystConsensusTarget US$29.14
Fair ValueUS$29.14
Share Pricen/a
Kestra Medical Technologies, Ltd. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
KMTS Community Narratives
AN
Fair Value US$29.14 6.3% undervalued intrinsic discount
Wearable Defibrillator Underpenetration Will Drive Long-Term Expansion In Cardiac Protection Adoption
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Wearable Defibrillator Underpenetration Will Drive Long-Term Expansion In Cardiac Protection Adoption
Catalysts About Kestra Medical Technologies Kestra Medical Technologies develops and leases the ASSURE wearable cardioverter defibrillator system to protect high risk cardiac patients during recovery and treatment optimization. What are the underlying business or industry changes driving this perspective?Read more
1
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$29.14
6.3% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
46.07% p.a.
Profit Margin
12.91%
Future PE
87.16x
Price in 2028
US$36.43
Trending Discussion
Recently Updated Narratives
AN
Wearable Defibrillator Underpenetration Will Drive Long-Term Expansion In Cardiac Protection Adoption
Fair Value: US$29.14 6.3% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Kestra Medical Technologies, Ltd. Key Details
Last Reported Earnings
Oct 31, 2025
Next Reporting Earnings
n/a
- -2.38
- 46.40%
- -186.89%
- 25.5%
About KMTS
- Founded
- 2014
- Employees
- 330
- CEO
- WebsiteView website
Kestra Medical Technologies, Ltd. operates as a wearable medical device and digital healthcare company. It focuses on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. The company’s develops and commercializes Cardiac Recovery System platform, a system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. Its platform provides ASSURE WCD, a wearable cardioverter defibrillator used to protect patients at an elevated risk of sudden cardiac arrest; and a suite of integrated digital solutions and services that enable enhanced patient and provider engagement and oversight with the objective of improving patient outcomes. The company was founded in 2014 and is based in Kirkland, Washington.
